Prostate cancer and active surveillance.
(2008) In Frontiers of Radiation Therapy and Oncology 41. p.41280-41280- Abstract
- This review outlines the different treatment options in localized prostate cancer. This information can be considered alongside other important factors, such as the individual patient's values and situation as well as the potential impact of treatment on his quality of life, in the treatment decision-making process. Taking all these factors into consideration, the data support active surveillance as an appropriate choice in patients with well or moderately differentiated, low-volume prostate cancer who have a life expectancy of less than 10 years. Men with higher-grade tumors and longer life expectancy may be at excess risk of death from prostate cancer managed with active surveillance.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1168916
- author
- Abrahamsson, Per-Anders LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Frontiers of Radiation Therapy and Oncology
- volume
- 41
- pages
- 41280 - 41280
- publisher
- Karger
- external identifiers
-
- wos:000258328000001
- pmid:18544979
- scopus:49449093298
- pmid:18544979
- ISSN
- 0071-9676
- DOI
- 10.1159/000139867
- language
- English
- LU publication?
- yes
- id
- bc0691fd-5b64-4d8a-9bc4-2ddd4142e6fe (old id 1168916)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18544979?dopt=Abstract
- date added to LUP
- 2016-04-04 09:13:44
- date last changed
- 2022-01-29 08:55:17
@article{bc0691fd-5b64-4d8a-9bc4-2ddd4142e6fe,
abstract = {{This review outlines the different treatment options in localized prostate cancer. This information can be considered alongside other important factors, such as the individual patient's values and situation as well as the potential impact of treatment on his quality of life, in the treatment decision-making process. Taking all these factors into consideration, the data support active surveillance as an appropriate choice in patients with well or moderately differentiated, low-volume prostate cancer who have a life expectancy of less than 10 years. Men with higher-grade tumors and longer life expectancy may be at excess risk of death from prostate cancer managed with active surveillance.}},
author = {{Abrahamsson, Per-Anders}},
issn = {{0071-9676}},
language = {{eng}},
pages = {{41280--41280}},
publisher = {{Karger}},
series = {{Frontiers of Radiation Therapy and Oncology}},
title = {{Prostate cancer and active surveillance.}},
url = {{http://dx.doi.org/10.1159/000139867}},
doi = {{10.1159/000139867}},
volume = {{41}},
year = {{2008}},
}